Toric iris-fixated phakic IOLs cause significant cell loss

Article

The annual cumulative cell loss in eyes implanted with toric iris-fixated phakic intraocular lenses (IOLs) is two to three times greater than in normal eyes without surgery.

The annual cumulative cell loss in eyes implanted with toric iris-fixated phakic intraocular lenses (IOLs) is two to three times greater than in normal eyes without surgery, according to the results of a study published in the February issue of the Journal of Refractive Surgery.

Mana Tehrani, MD from the Johannes Gutenburg-University, Mainz and Burkhard Dick, MD from the Center for Vision Science, Ruhr University Eye Hospital, Bochum, Germany conducted a prospective, randomized, self-controlled clinical trial of 40 eyes (28 myopic, 12 hyperopic) of 23 patients with high ametropia and astigmatism. Non-contact computer-assisted endothelial microscopy was performed before implantation and one, two and three years after.

The mean preoperative cell count in the myopic group was 3,179±531 cells/mm2 (range: 1,800 to 3,900 cells/mm2). The mean intra-individual cell loss was -1.83±2.25% in the first year, -1.83±2.95% in the second year and -3.20±4.43% in the third year. In the hyperopic group, mean preoperative cell count was 3,107±125 cells/mm2 (range: 2,932 to 3,300 cells/mm2). The mean cell loss was -1.63±1.76% in the first year, 0.05±1.25% in the second year and -2.88±2.03% in the third year. The annual cumulative cell loss was -1.9% and -1.6% for the myopic and hyperopic groups respectively.

The authors concluded that such as high cell loss means that an endothelial cell count analysis should be performed annually in order to detect potential progressive cell loss at an early stage.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.